In one of the initial studies, Lissoni and coworkers observed that, in patients with an advanced cancer of vascular endothelial growth factor (VEGF), melatonin may control the tumor growth, at least in part, by acting as a natural antiangiogenic molecule [65]. The gene discussed is VEGFA; the disease is cancer.